1190319-59-5 Usage
Uses
Used in Pharmaceutical Industry:
1H-pyrrolo[2,3-c]pyridine-4-carbonitrile is used as a building block for the synthesis of various drugs and bioactive molecules due to its versatile reactivity and ability to introduce the pyrrolopyridine moiety into diverse chemical structures.
Used in Drug Discovery and Development:
PP4CN is used as an important molecule in drug discovery and development, leveraging its potential biological activities and complex molecular structure to create novel therapeutic agents.
Used in Materials Science:
1H-pyrrolo[2,3-c]pyridine-4-carbonitrile is used in materials science for its unique electronic and optical properties, which can be harnessed for the development of advanced materials with specific functionalities.
Used in Organic Electronics:
PP4CN is used in organic electronics due to its electronic properties, which can contribute to the design and fabrication of organic electronic devices and components.
Check Digit Verification of cas no
The CAS Registry Mumber 1190319-59-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,0,3,1 and 9 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1190319-59:
(9*1)+(8*1)+(7*9)+(6*0)+(5*3)+(4*1)+(3*9)+(2*5)+(1*9)=145
145 % 10 = 5
So 1190319-59-5 is a valid CAS Registry Number.
1190319-59-5Relevant articles and documents
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00639, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS
-
Page/Page column 38, (2013/07/05)
Compounds having the formula I wherein A, Rla, Rlb, R2, R3, R4, R5, R6, R7, Rs, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders
